July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Clinical application of Retinal Biomarkers in Diabetic Retinopathy Patients.
Author Affiliations & Notes
  • ida ceravolo
    University of Messina, Anoia, Italy
  • Giovanni William Oliverio
    University of Messina, Anoia, Italy
  • Costantino John Trombetta
    University of Messina, Anoia, Italy
  • Footnotes
    Commercial Relationships   ida ceravolo, None; Giovanni William Oliverio, None; Costantino John Trombetta, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 6549. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      ida ceravolo, Giovanni William Oliverio, Costantino John Trombetta; Clinical application of Retinal Biomarkers in Diabetic Retinopathy Patients.. Invest. Ophthalmol. Vis. Sci. 2019;60(9):6549.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the presence of specific swept-source optical coherence tomography (SS-OCT) retinal biomarkers for inflammation or vasculogenic disorder in patients with diabetic macular edema (DME) to identify a target therapy for each patients.
A retrospective analysis on the SS-OCT data in a cohort of patients (treatment naïve) without any concomitant macular diseases.

Methods : This study involved 65 eyes of 46 patients divided in three treatment groups. In anti-VEGF group 20 eyes received 3 monthly intravitreal injections of Ranibizumab, in Dexamethasone group 20 eyes received intravitreal implant of dexamethasone, in laser group 25 eyes treated with multispot (focal/grid) laser photocoagulation (Pascal, Topcon®).
All patients underwent full ophthalmologic examination at baseline (V1) and after six months from the treatment (V2), with best-corrected visual acuity (BCVA, ETDRS charts), fundus photograph, SS-OCT (Triton-plus Topcon) radial 9x9 mm focused on the macular area.
The biomarkers evaluated were: number of hyper reflective retinal spots (HRS), central retinal thickness (CRT), serous detachment of neuroepithelium (SDN),vitreo-macular adhesion, epiretinal membrane, turn-over of red-dots, intraretinal cysts (IRC) and Choroidal thickness. The changes between V1 and V2 were assessed by Wilcoxon test, the differences between the three groups of treatment were calculated by Mann Whitney test, considering a p<0.005 statistically significant.

Results : At V2 in all groups BCVA improved (p<0.005), otherwise a significantly decrease in CRT p=0.001, IRC p=0.001, SDN p=0.013, HRS p=0.023, Red Dots p=0.021 was observed. There was no significant changes in the Choroidal thickness.
In anti-VEGF group BCVA improved p= 0.007 and decreased CRT p=0.009, IRC p=0.003, HRS p=0.09 Red Dots p=0.025 and there was no statistically significant changes of Choroidal thickness and SDN at V2. In dexamethasone group BVA improved p=0.040 and decreased CRT p=0.004, IRC p= 0.011, SDN p=0.046 and Choroidal thickness p=0.047 at V2. In laser group laser only CRT decreased p=0.033 and there was no statistically significant changes of Choroidal thickness and SDN at V2.

Conclusions : Biomarkers of chronic inflammation (SDN and choroidal thickness) were improved only in the group of patients treated with intravitreal implant of dexamethasone.Therefore, the occurrence of such OCT retinal biomarkers may be used to influence clinical decisions for treatment.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×